Breast Cancer | Specialty

O'Shaughnessy Provides Fresh Insights Into Specificity in TNBC Therapy

August 25th 2014

Although no cytotoxic agents are currently correlated with specific subtypes of triple negative breast cancer (TNBC), recent findings indicate that targeting genomic stability, antimetastatic mechanisms, and protein expression characteristics are promising approaches for future TNBC treatments.

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

August 22nd 2014

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

August 21st 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21st 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

August 18th 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Pfizer Seeks FDA Approval for Palbociclib

August 18th 2014

Pfizer has submitted a New Drug Application for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer, based on findings from the phase II PALOMA-1 trial.

Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

August 14th 2014

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

Favorable Safety Profile of T-DM1 Confirmed in Large Study

August 13th 2014

The favorable safety profile of T-DM1 makes it apt to be looked at in other settings of breast cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

Dr. Brufsky Discusses Future Research into Bisphosphonates

August 11th 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

Utilizing Bisphosphonates in Breast Cancer

August 7th 2014

TEXT/SOFT Findings in HR-Positive Breast Cancer

August 7th 2014

Adjuvant Everolimus and CDK4/6 Trials in Breast Cancer

August 7th 2014

Managing the Toxicity of Everolimus in Breast Cancer

August 7th 2014

Second-Line Everolimus in Metastatic Breast Cancer

August 7th 2014

Frontline Treatment of ER-Positive Breast Cancer

August 7th 2014

T-DM1 Plus Pertuzumab in the MARIANNE Trial

August 7th 2014

Fitting T-DM1 Into Established Upfront Treatment Paradigms

August 7th 2014

Utilizing pCR in Breast Cancer Trials

August 7th 2014

Upfront T-DM1 in HER2-Positive Breast Cancer

August 7th 2014